Both anti-EGFR monoclonal antibodies prevent ligand binding and interrupt EGF signalling cascade; these data suggest that anti-EGFR antibody-Ab5 interaction may have some kind of early positive effects on LAM/TSC cells before becoming toxic. Here, EGFR is linked to lymphangioleiomyomatosis.